TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Phenomenological and Psychopathological Factors Associated to Hallucinations in Parkinson's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years-old~* Absence of opposition from the patient himself/herself or his/her legal representant for his/her participation to the study~* Patient without superior age limit with a diagnosis of Parkinson's disease made according to the UKPDSBB criteria (UK Parkinson's Disease Society Brain Bank clinical diagnostic criteria)~* Outpatient consulting in neurology at the Charpennes'hospital~Exclusion Criteria:~* Opposition to the study~* Deafness or blindness which could compromise the interview

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients affected by Parkinson's disease (Type: None): Outpatients affected by Parkinson's Disease consulting in neurology can be included if volunteer

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Investigate the Safety and Efficacy of LT-02 in Patients With Mesalamine Refractory Ulcerative Colitis (UC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Established diagnosis of ulcerative colitis (UC), based on clinical history, exclusion of infectious causes, and characteristic endoscopic and histologic findings.~2. Active UC with disease confirmed by endoscopy findings and confirmed by central reader.~3. A modified Mayo Score 4-10, and with a centrally read endoscopy score activity of ≥ 2 points.~4. Mesalamine (5-ASA) refractory.~Exclusion Criteria:~1. Diagnosis of Crohn's disease, indeterminate colitis, ischemic colitis, radiation colitis, microscopic colitis (i.e., collagenous colitis and lymphocytic colitis), diverticular disease associated colitis,~2. Toxic megacolon or fulminant colitis,~3. Prior colon resection,~4. Evidence of infectious colitis (e.g., pathogenic bacteria or Clostridium difficile infection) at screening,~5. Known celiac disease~6. Other inflammatory or bleeding disorders of the colon and intestine, or diseases what may cause diarrhea or gastrointestinal bleeding~7. History or presence of ischemic heart disease, myocardial infarction, peripheral arterial disease, ischemic stroke, or transient ischemic attack,~8. Subjects with known hypersensitivity to soy,~9. Treatment with methotrexate, azathioprine, 6-mercaptopurine TNF-alpha-antagonists, vedolizumab or certolizumab pegol, tacrolimus, or anti-integrin therapy within last 8 weeks prior to screening,~10. Treatment with any (topical or systemic) corticosteroid formulation for the treatment of IBD within last 7 days prior to endoscopy,~11. Treatment with other investigational drug within last 8 weeks prior to screening,

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- LT-02 (Type: EXPERIMENTAL): 1.6 g PC in LT-02 BID
- LT-02 Placebo (Type: PLACEBO_COMPARATOR): 0 g PC in LT-02 Placebo BID

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of CHF6297 in Healthy Subjects and Patients With COPD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~Part 1, Part 2, Part 4 (Healthy subjects):~* Male subjects aged 18-55 years;~* Non smokers~* Lung function above 80% of predicted normal value~* Healthy subjects based on medical evaluation including medical history, physical examination, laboratory tests and cardiac testing~* ability to produce an adequate induced sputum sample (study part 4 only)~Part 3 (COPD patients):~* Males and females aged 40-75 years~* Current or past smokers~* stable patients with a post-bronchodilator FEV1 between 40 and 80% of predicted normal value and FEV1/FVC ratio \<0.7~* Ability to produce a spontaneous and an adequate induced sputum sample~Exclusion Criteria:~Parts 1,2, 4 (Healthy subjects):~* Any clinically relevant abnormalities and/or uncontrolled diseases~* Abnormal laboratory values~* Recent respiratory tract infection~* Hypersensitivity to the drug or excipients~* Positive serology results~* Positive cotinine, alcohol, drug of abuse tests~Part 3 (COPD patients):~* Females of childbearing potential~* History of asthma~* Unstable concomitant diseases~* Abnormal relevant Holter ECG parameters~* Recent acute exacerbations of COPD or respiratory tract infection~* Hypersensitivity to the drug or excipients~* Positive serology results

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- CHF6297 Active (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Participants With Nonalcoholic Steatohepatitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Successful completion of both Treatment Period 1 and Treatment Period 2, of the CENTAUR Study (652-2-203), including a Year 2 liver biopsy.~* Completed the AURORA study (3152-301-002) as a result of reaching an adjudicated liver-related clinical outcome in Part 1 or Part 2 of the study of:~* Histopathological progression to cirrhosis~* Model for end-stage liver disease (MELD) score ≥ 15~* Ascites (requiring intervention, ie, large volume paracentesis ≥ 1L or initiation of a diuretic)~* Hospitalization (as defined by a stay of ≥ 24 hours) for onset of variceal bleed, hepatic encephalopathy (defined by a West Haven Stage of ≥ 2), spontaneous bacterial peritonitis (confirmed by diagnostic paracentesis with positive ascitic fluid bacterial culture).~Exclusion Criteria:~* Prior or planned liver transplantation~* Other know causes of chronic liver disease such as: Alcoholic liver disease, Primary biliary cirrhosis, Primary sclerosing cholangitis, Autoimmune hepatitis, Wilson's disease, hemochromatosis, or iron overload, or Alpha-1 antitrypsin (A1AT) deficiency.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Cenicriviroc (CVC) 150 mg (Type: EXPERIMENTAL): Cenicriviroc 150 mg tablet once daily in the morning with food until the study was terminated (up to approximately 4 years).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Oral Ketamine in the Treatment of Depression and Anxiety in Patients With Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with cancer~* Outpatient status at the time of study entry~* 18 years of age or older~* Life expectancy of at least 1 month~* Regular access to a telephone (for safety reasons)~* Reliable transportation to follow-up visits~* Caregiver observation available for 24 hours after the dose~* Histologically-proven malignancy~* Depression score of \>11 on the Hospital Anxiety and Depression Scale (HADS)~* Provision of informed consent~* Able to complete the patient questionnaires alone or with assistance~* Able to speak and read English~* May receive other psycho-active medications while on the study i.e. opiates, except as defined within the exclusion criteria~* May receive psychotherapy from an outside provider at the beginning and/or during the course of the study~Exclusion Criteria:~* Obvious cognitive dysfunction or Mini Mental Status Exam score \<20~* Antidepressants started or dose changed within 8 weeks of the beginning of the study or during the study~* Benzodiazepines prescribed for psychiatric indications that have been started or dose change within 2 weeks of the beginning of study enrollment~* Suicidal ideation or a suicide attempt within the last year~* Patients with current or past psychosis not from delirium~* Females who are pregnant or nursing~* Unable to take oral medications~* Primary or metastatic brain malignancy~* Gastrointestinal tract obstruction~* Prior adverse reaction to or other contraindication to ketamine~* Substance abuse or dependence, as defined by Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) criteria, within the last 90 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ketamine (Type: EXPERIMENTAL): Single dose of ketamine (0.5 mg/kg)
- Placebo (Type: PLACEBO_COMPARATOR): Single dose of placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Transjugular Intrahepatic Portosystemic Shunt With 8- or 10-mm Covered Stents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All consecutive cirrhotic patients who have undergone TIPS at our Department for bleeding of esophagogastric varices refractory to medical or endoscopic treatment or for ascites/hydrothorax refractory to diuretic therapy will be considered eligible for the study.~Exclusion Criteria:~* an age \>75 years; past or present history of hepatic encephalopathy;~* a Z-score at trial making test-A (TMT-A) \>1.5;~* bilirubine levels \>5 mg/dl;~* creatinine levels \>3 mg/dl;~* serious cardiac or pulmonary dysfunction;~* a Child-Pugh's score \>11;~* a model end-stage liver disease (MELD) score \>18;~* portal thrombosis;~* a diagnosis of hepatic carcinoma;~* sepsis;~* spontaneous bacterial peritonitis;~* renal insufficiency.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): patients treated with 10 mm stent
- 2 (Type: ACTIVE_COMPARATOR): patients treated with 8 mm stent

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Visual Motor Coordination

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
* INCLUSION CRITERIA:~Inclusion Criteria for Normal Volunteers:~In order to be eligible to participate in this study, an individual must meet all of the following criteria:~1. Participant must be a volunteer with no ocular, visual, or oculomotor problems.~2. Participant must be 18 years old or older.~3. Participant must be able to follow directions and actively pay attention to visual stimuli and respond as appropriate.~4. For studies which use the contact lens, participant must be able to tolerate a contact lens in either one or both eyes.~Inclusion Criteria for Patients:~In order to be eligible to participate in this study, an individual must meet all of the following criteria~1. Participant must be 18 years old or older.~2. Participant must be able to follow directions and actively pay attention to visual stimuli and respond as appropriate.~3. For studies which use the contact lens, participant must be able to tolerate a contact lens in either one or both eyes.~EXCLUSION CRITERIA:~Exclusion Criteria for Normal Volunteers:~An individual who meets any of the following criteria will be excluded from participation in this~study:~An individual who meets any of the following criteria will be excluded from participation in thisstudy:~1. Participant has a history of ocular or visual diseases or diseases affecting the nervous system (including myasthenia, MS, etc.) or any diseases which might affect control of eye movements or affect vision.~2. Participant has had prior eye or eye muscle surgery.~3. Participant has a history of eye patching (amblyopia or lazy eye).~4. Participant currently uses eye drops or ocular medications.~Exclusion Criteria for Patients:~An individual who meets any of the following criteria will be excluded from participation in this study:~1. Patient is unable to cooperate with testing, including sitting still while eye movements are recorded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: t

Study Arms:
- Normal Volunteer (Type: None): Healthy subjects without neurodegenerative diseases
- Patients (Type: None): Subjects with neurodegenerative diseases

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Stellate Ganglion Block on Hot Flashes in Hispanic Women With Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Hispanic or Spanish speaking women aged 30 to 70 years~2. 28 or more reported moderate-to-very severe hot flashes per week~3. a minimum of two weeks of VMS diary recording prior to SGB~4. current use of tamoxifen, aromatase inhibitors, or SERMs for a breast cancer indication for at last six months~5. willingness to undergo fluoroscopy-guided SGB or sham treatment.~6. if participant is on an SSRI,SNRI or membrane stabilizer (pregabalin, gabapentin, for example), it must be a stable, unchanged dose for previous 3 months~Exclusion Criteria:~1. conditions that preclude SGB or sham intervention (e.g., anatomic abnormalities of the anterior neck or cervical spine; goiter, cardiac/pulmonary compromise; acute illness/infection; coagulopathy or bleeding disorder; allergic reactions/contraindications to a local anesthetic or contrast dye); pregnancy 2. use of treatments in the past 2 months that can affect VMS (e.g., use of oral or transdermal HT or contraceptives,~-

- Gender: FEMALE
- Minimum Age: 30 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Bupivicaine (Type: ACTIVE_COMPARATOR): Stellate Ganglion Block Injection with bupivicaine
- Saline (Type: SHAM_COMPARATOR): Saline injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Continuous Pressure Monitoring In Lower Leg Fractures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 16 years of age and older, presenting for treatment in 24 hours or less~* Diaphyseal or bicondylar plateau fracture of the tibia~Exclusion Criteria:~* Patients under 16 years of age~* Patients who present to VGH more than 24 hours after the injury~* Patients who are not mentally competent to give Informed Consent

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Focused Cognitive Testing in Inpatients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Elective inpatients, living in the canton of lucerne, high risk of developing a major neurocognitive disorder, living at home~Exclusion Criteria:~* Known mental disorder according to ICD-10, chapter V, excluding F32 \& F33, patients with terminal illness, patients of intensive care unit or oncology patients, no adequate vision or hearing, no ability to speak, write or to understand German, no Informant, antidementia medication

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention-Group (Type: EXPERIMENTAL): None
- Control-Group (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of Homeopathic Potassium Dichromate to Treat Tracheal Secretions in Critically Ill Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients 18yrs and older~* Situated in the Critical Care areas of Sunnybrook Health Sciences Centre including the Critical Care Unit, Cardiovascular Surgery Intensive Care Unit, Ross Tilley Burn Centre and B5/D4 intensive care units.~* They will have been weaned from mechanical ventilation (eg: extubated, face mask or tracheostomy mask, minimal pressure support or CPAP, FiO2 \<0.3) but are unable to be transferred out of the unit due to excessive and/or persistent secretions for at least 48 hours.~* Persistent secretions will be defined as suctioning of greater than every 2 hours or a score of greater than 20-24 MP per day. (In the Critical Care areas, each time a patient is suctioned, secretions are quantified on a scale of 1-3, with MP being mucopurulent in nature).~Exclusion Criteria:~* Those with evidence of untreated respiratory infections or infections treated for less than 48 hours.~* Those patients on high dose steroids as defined by greater than:Fluticasone 125ug inhaler- four puffs twice daily and/or Prednisone 20mg daily orally~* Patients with multiple drug and/or environmental allergies~* Those patients who fail to give informed written consent.~* Those patients currently enrolled in another clinical trial or who have been approached for participation in a trial during the last 30 days.~* Previous enrollment in this study~* Pregnancy- all women of child bearing age will be administered a pregnancy test before inclusion into the study to verify their status.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Visual Field Restoration in Patients With Post-stroke Homonymous Hemianopsia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Presence of an homonymous visual field amputation after vascular retrochiasmatic lesion of the occipital region (visual cortex alone or with optical radiations or with other associated occipital areas)~* inclusion 3 months to 36 months after stroke~* Patients aged 18 years and older~Exclusion criteria:~* Brain injury history~* Severe neuropsychological, psychiatric or behavioral disorder~* Severe eye disorder or visual impairment (visual acuity less than 3/10)~* Progressive eye disorder (cataracts or glaucoma)~* insufficient French language proficiency to understand the questionnaires and rehabilitation tasks~* patient under legal protection~* patient's opposition to participate in the study~* no medical insurance coverage~* pregnant pr breastfeeding patient

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- immediate rehabilitation (Type: EXPERIMENTAL): None
- delayed rehabilitation (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues